CCLaunty
2021-11-25
👍
Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook以20%折扣发行股票筹集5000万美元后股价暴跌</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":874574255,"tweetId":"874574255","gmtCreate":1637806401607,"gmtModify":1637806401607,"author":{"id":4097397237133540,"idStr":"4097397237133540","authorId":4097397237133540,"authorIdStr":"4097397237133540","name":"CCLaunty","avatar":"https://static.tigerbbs.com/cac20c3eb0c4baab5ee77afa74663b07","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874574255","repostId":1182883462,"repostType":4,"repost":{"id":"1182883462","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637765117,"share":"https://www.laohu8.com/m/news/1182883462?lang=zh_CN&edition=full","pubTime":"2021-11-24 22:45","market":"us","language":"en","title":"Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook以20%折扣发行股票筹集5000万美元后股价暴跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1182883462","media":"Benzinga","summary":"Outlook shares plunged more than 22% in early trading.Outlook Therapeutics Inc has increased the siz","content":"<p>Outlook shares plunged more than 22% in early trading.<img src=\"https://static.tigerbbs.com/400d88d0cf7a467f2553f97a56faba44\" tg-width=\"868\" tg-height=\"610\" referrerpolicy=\"no-referrer\"><b>Outlook Therapeutics Inc</b> has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.</p><p><blockquote>Outlook股价早盘暴跌逾22%。<b>展望治疗公司</b>已将之前宣布的公开发行规模增加至4000万股，每股1.25美元，总收益为5000万美元。此次要约价格较周二最后收盘价1.56美元有近20%的折扣。</blockquote></p><p> Previously, the Company offered 8 million shares at $1.25 per share.</p><p><blockquote>此前，该公司以每股1.25美元的价格发行了800万股股票。</blockquote></p><p> The offering will close by November 29.</p><p><blockquote>此次发行将于11月29日结束。</blockquote></p><p> H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.</p><p><blockquote>H.C.Wainwright&Co.担任此次发行的唯一账簿管理人。</blockquote></p><p> GMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.</p><p><blockquote>GMS Ventures and Investments是Outlook Therapeutics最大股东和战略合作伙伴BioLexis Pte.的子公司。Ltd.已表示有兴趣直接或通过附属公司购买最多2000万美元的此次发行股票。</blockquote></p><p> Outlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.</p><p><blockquote>Outlook Therapeutics将把净收益用于营运资金和一般公司用途，包括支持其ONS-5010开发计划。</blockquote></p><p> Recently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.</p><p><blockquote>最近，Outlook在AAO 2021年年会视网膜亚专科日上展示了ONS-5010 3期NORSE TWO试验的关键安全性和有效性数据。</blockquote></p><p> ONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,</p><p><blockquote>ONS-5010是贝伐珠单抗的一种在研眼科制剂，用于湿性年龄相关性黄斑变性（湿性AMD）和其他视网膜适应症，</blockquote></p><p> Outlook Therapeutics plans to submit a marketing application in Q1 of 2022.</p><p><blockquote>Outlook Therapeutics计划于2022年第一季度提交营销申请。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook以20%折扣发行股票筹集5000万美元后股价暴跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Shares Plunges After Raising $50M Via Equity Offering Issued At 20% Discount<blockquote>Outlook以20%折扣发行股票筹集5000万美元后股价暴跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-11-24 22:45</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Outlook shares plunged more than 22% in early trading.<img src=\"https://static.tigerbbs.com/400d88d0cf7a467f2553f97a56faba44\" tg-width=\"868\" tg-height=\"610\" referrerpolicy=\"no-referrer\"><b>Outlook Therapeutics Inc</b> has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.</p><p><blockquote>Outlook股价早盘暴跌逾22%。<b>展望治疗公司</b>已将之前宣布的公开发行规模增加至4000万股，每股1.25美元，总收益为5000万美元。此次要约价格较周二最后收盘价1.56美元有近20%的折扣。</blockquote></p><p> Previously, the Company offered 8 million shares at $1.25 per share.</p><p><blockquote>此前，该公司以每股1.25美元的价格发行了800万股股票。</blockquote></p><p> The offering will close by November 29.</p><p><blockquote>此次发行将于11月29日结束。</blockquote></p><p> H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.</p><p><blockquote>H.C.Wainwright&Co.担任此次发行的唯一账簿管理人。</blockquote></p><p> GMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.</p><p><blockquote>GMS Ventures and Investments是Outlook Therapeutics最大股东和战略合作伙伴BioLexis Pte.的子公司。Ltd.已表示有兴趣直接或通过附属公司购买最多2000万美元的此次发行股票。</blockquote></p><p> Outlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.</p><p><blockquote>Outlook Therapeutics将把净收益用于营运资金和一般公司用途，包括支持其ONS-5010开发计划。</blockquote></p><p> Recently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.</p><p><blockquote>最近，Outlook在AAO 2021年年会视网膜亚专科日上展示了ONS-5010 3期NORSE TWO试验的关键安全性和有效性数据。</blockquote></p><p> ONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,</p><p><blockquote>ONS-5010是贝伐珠单抗的一种在研眼科制剂，用于湿性年龄相关性黄斑变性（湿性AMD）和其他视网膜适应症，</blockquote></p><p> Outlook Therapeutics plans to submit a marketing application in Q1 of 2022.</p><p><blockquote>Outlook Therapeutics计划于2022年第一季度提交营销申请。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182883462","content_text":"Outlook shares plunged more than 22% in early trading.Outlook Therapeutics Inc has increased the size of the previously announced public offering to 40 million shares at $1.25 per share, for gross proceeds of $50 million. The offer price represents a discount of almost 20% from the last close price of $1.56 on Tuesday.\nPreviously, the Company offered 8 million shares at $1.25 per share.\nThe offering will close by November 29.\nH.C. Wainwright & Co. is acting as the sole book-running manager for the offering.\nGMS Ventures and Investments, an affiliate of Outlook Therapeutics' largest stockholder and strategic partner, BioLexis Pte. Ltd., has indicated an interest in purchasing directly or through an affiliate up to $20 million of the shares in the offering.\nOutlook Therapeutics will use the net proceeds for working capital and general corporate purposes, including supporting its ONS-5010 development program.\nRecently, Outlook presented pivotal safety and efficacy data from the Phase 3 NORSE TWO trial for ONS-5010 at the Retinal Subspecialty Day, AAO 2021 Annual Conference.\nONS-5010 is an investigational ophthalmic formulation of bevacizumab for use in wet age-related macular degeneration (wet AMD) and other retinal indications,\nOutlook Therapeutics plans to submit a marketing application in Q1 of 2022.","news_type":1,"symbols_score_info":{"OTLK":0.9}},"isVote":1,"tweetType":1,"viewCount":911,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/874574255"}
精彩评论